Commentary

Radiomics: The endocrinologists’ new best friend?

Adrian T. Billeter, Beat P. Müller-Stich*

Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Im Neuenheimer Feld 420, Heidelberg 69120, Germany

ARTICLE INFO

Article History:
Received 18 July 2021
Accepted 22 July 2021
Available online xxx

We have read with great interest the study by Shi et al. investigating adipose tissue textures in patients with metabolic diseases and weight loss after metabolic surgery [1]. They used abdominal computer tomography (CT) slices to assess volume and textures of visceral and subcutaneous adipose tissue. Using machine learning and neural networks to identify clinical and CT-based markers (radiomics), Shi et al. were able to identify patients developing metabolic disease with a high predictive value. Furthermore, a combination of different radiomic markers were able to predict weight loss after bariatric surgery. The most important radiomic parameter identified was “runentropy”, which is defined as “the uncertainty/randomness in the distribution of run lengths and gray levels”.

This study investigated an important and relevant topic. Traditional parameters used for metabolic health such as weight, body mass index (BMI) and others are unreliable and do not accurately predict survival and development of metabolic diseases. Sharma et al. showed years ago that BMI is a poor predictor for survival and therefore proposed the Edmonton Obesity Staging System to identify patients at risk for detrimental outcomes due to obesity associated diseases [2,3]. Similarly, several other studies showed that obese patients can be metabolically healthy while lean patients can have a high cardiovascular risk [4,5]. Therefore, it is of paramount interest for the treatment of metabolic diseases to reliably identify the patients having the highest risk for cardiovascular events or development of microvascular complications and, consequently, benefitting the most from an early intervention. This study presents an important step in this direction.

However, there are also several points that must be addressed in future studies. The patients in this study were relatively healthy, even the patients in the group with obesity and metabolic syndrome. Average HbA1c levels were normal in the obese patients and there were no separate data on patients with more severe metabolic disease. Similarly, while the authors mention that radiomics was able to differentiate patients with and without type 2 diabetes and non-alcoholic fatty liver disease, there were no detailed information on these subgroups provided. Furthermore, there were also no detailed information on the patients undergoing bariatric surgery regarding preoperative BMI and comorbidities as well as remission of the comorbidities and the predictive value of radiomic assessment for remission of comorbidities.

To use radiomics in daily practice, the results of this study must be validated in a wide variety of patients with varying severity of type 2 diabetes and over a wide BMI-range. Furthermore, it would be important to assess whether the radiomic parameters chosen can be used to assess the risk for cardiovascular events and other detrimental events in metabolically sick patients. Early identification of patients with a high risk for cardiovascular events and other complications of their metabolic disease such as nephropathy and liver cirrhosis is of paramount interest for best care. If radiomics is predictive for complications of metabolic diseases, a specific treatment, be it medically or surgically, can be started early since the effectiveness of treatments for metabolic disease, such as metabolic surgery, is higher the earlier it is started [6]. It should also be investigated whether radiomics maintain their predictive value after treatment of metabolic diseases. In the current manuscript, only the improvement of insulin resistance as a metabolic endpoint after metabolic surgery was analyzed. The biggest value of the proposed radiomics would be to predict detrimental metabolic outcomes and treatment response.

Another open question is which changes in the adipose tissue are detected by these CT-based parameters. The parameter described as “run entropy” seems to be in line with the changes observed in adipose tissue of patients with advanced metabolic disease. Several studies showed that insulin resistance is associated with increased adipose tissue fibrosis and in particular with changes in the omental fat. The findings described in this study also found that the omental fat changes have a stronger predictive value than subcutaneous fat changes [7–10]. Since more advanced metabolic disease is associated with stronger changes in the adipose tissue, it seems possible that the CT-based parameters may be able to differentiate also patients with more advanced metabolic disease than the patients investigated in the current study [10].

DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2021.103471.
* Corresponding author.
E-mail address: beat.mueller@med.uni-heidelberg.de (B.P. Müller-Stich).

https://doi.org/10.1016/j.ebiom.2021.103531
2352-3964/© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Studies like this present an important step towards a better understanding of metabolic diseases and offer the opportunity for more personalized care in patients with metabolic diseases.

Declaration of Competing Interest

The authors have no conflict of interest to disclose.

References

[1] Shi J, Bao G, Hong J, Wang S, Chen Y, Zhao S, et al. Deciphering CT texture features of human visceral fat to evaluate metabolic disorders and surgery-induced weight loss effects. EBioMedicine 2021;69. doi:10.1016/j.ebiom.2021.103471.

[2] Kuk JL, Ardern CI, Church TS, Sharma AM, Padwal R, Sui X, et al. Edmonton obesity staging system: association with weight history and mortality risk. App Physiol Nutr Metab 2011;36:570–6.

[3] Padwal RS, Pajewski NM, Allison DB, Sharma AM. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ Can Med Assoc J 2011;183:E1059–66.

[4] Hinnouho GM, Czernichow S, Dugravot A, Nah H, Brunner EJ, Kivimaki M, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. Eur Heart J 2015;36:551–9.

[5] Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 2008;168:1617–24.

[6] Carlsson LMS, Sjoholm K, Karlsson C, Jacobson P, Andersson-Assarsson JC, Svensson PA, et al. Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study. Lancet Diabetes Endocrinol 2017;5:271–9.

[7] Kenngott HG, Nickel F, Wise PA, Wagner F, Billeter AT, Nattermüller J, et al. weight loss and changes in adipose tissue and skeletal muscle volume after laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass: a prospective study with 12-month follow-up. Obes Surg 2019;29:4018–28.

[8] Divoux A, Tordjman J, Lacasa D, Veyne N, Hugol D, Aissat A, et al. Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes 2010;59:2817–25.

[9] Guglielmi V, Cardellini M, Cinti F, Corgosinho F, Cardolini I, D’Adamo M, et al. Omental adipose tissue fibrosis and insulin resistance in severe obesity. Nutr Diabetes 2015;5:e175.

[10] Marcelin G, Silvera ALM, Martins LB, Ferreira AV, Clement K. Deciphering the cellular interplays underlying obesity-induced adipose tissue fibrosis. J Clin Invest 2019;129:4032–40.